Overall, while both BAFF/APRIL-targeted therapies and BTK inhibitors aim to modulate dysfunctional B cell responses in autoimmune diseases, they operate via distinct mechanisms, exhibit varying clinical efficacies and safety profiles, and may require different approaches in patient management and precision medicine. This evidence concerns the gene BTK and autoimmune disease.